• NextCure posted a Q2 net loss of USD 14.89 million, narrowing from a USD 26.81 million loss a year earlier.
• R&D expense fell 69.18% to USD 7.43 million; G&A expense declined 18.74% to USD 2.59 million.
• Asset impairment charges were USD 5.08 million; cash, cash equivalents and marketable securities totaled USD 20.09 million at June 30, down from USD 41.82 million at Dec. 31.
• Signed a definitive all-stock merger deal with Avere Therapeutics; the combined company is expected to trade as Avere under ticker “AVRX”.
• Management said it is preserving capital to support a second-half 2026 close; Avere’s concurrent private financing targets about USD 320 million gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9805542) on August 06, 2026, and is solely responsible for the information contained therein.